Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours
Chemokine receptor CXCR4 is overexpressed in neoplasms and its expression is related to tumour invasion, metastasis and aggressiveness. <sup>68</sup>Ga-Pentixafor is used to non-invasively image the expression of CXCR4 in tumours and has been widely used in haematological malignancies. R...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/9/2135 |
| _version_ | 1797489488273866752 |
|---|---|
| author | Bawinile Hadebe Machaba Michael Sathekge Colleen Aldous Mariza Vorster |
| author_facet | Bawinile Hadebe Machaba Michael Sathekge Colleen Aldous Mariza Vorster |
| author_sort | Bawinile Hadebe |
| collection | DOAJ |
| description | Chemokine receptor CXCR4 is overexpressed in neoplasms and its expression is related to tumour invasion, metastasis and aggressiveness. <sup>68</sup>Ga-Pentixafor is used to non-invasively image the expression of CXCR4 in tumours and has been widely used in haematological malignancies. Recent evidence shows that therapies targeting CXCR4 can increase the chemosensitivity of the tumour as well as inhibit tumour metastasis and aggressiveness. <sup>68</sup>Ga-Pentixafor has shown promise as an elegant radiotracer to aid in the selection of patients whose tumours demonstrate CXCR4 overexpression and who therefore may benefit from novel therapies targeting CXCR4. In addition, its therapeutic partners <sup>177</sup>Lu- and <sup>90</sup>Y-Pentixather have been investigated in the treatment of patients with advanced haematological malignancies, and initial studies have shown a good treatment response in metabolically active lesions. <sup>68</sup>Ga-Pentixafor in solid tumours complements <sup>18</sup>F-FDG by providing prognostic information and selecting patients who may benefit from therapies targeting CXCR4. This review summarises the available literature on the potential applications of <sup>68</sup>Ga-Pentixafor in solid tumours. |
| first_indexed | 2024-03-10T00:17:19Z |
| format | Article |
| id | doaj.art-c8f7c765c4af499cbcd361067f604ac8 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T00:17:19Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-c8f7c765c4af499cbcd361067f604ac82023-11-23T15:49:23ZengMDPI AGDiagnostics2075-44182022-09-01129213510.3390/diagnostics12092135Current Status of <sup>68</sup>Ga-Pentixafor in Solid TumoursBawinile Hadebe0Machaba Michael Sathekge1Colleen Aldous2Mariza Vorster3Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South AfricaDepartment of Nuclear Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South AfricaDepartment of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban 4058, South AfricaDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South AfricaChemokine receptor CXCR4 is overexpressed in neoplasms and its expression is related to tumour invasion, metastasis and aggressiveness. <sup>68</sup>Ga-Pentixafor is used to non-invasively image the expression of CXCR4 in tumours and has been widely used in haematological malignancies. Recent evidence shows that therapies targeting CXCR4 can increase the chemosensitivity of the tumour as well as inhibit tumour metastasis and aggressiveness. <sup>68</sup>Ga-Pentixafor has shown promise as an elegant radiotracer to aid in the selection of patients whose tumours demonstrate CXCR4 overexpression and who therefore may benefit from novel therapies targeting CXCR4. In addition, its therapeutic partners <sup>177</sup>Lu- and <sup>90</sup>Y-Pentixather have been investigated in the treatment of patients with advanced haematological malignancies, and initial studies have shown a good treatment response in metabolically active lesions. <sup>68</sup>Ga-Pentixafor in solid tumours complements <sup>18</sup>F-FDG by providing prognostic information and selecting patients who may benefit from therapies targeting CXCR4. This review summarises the available literature on the potential applications of <sup>68</sup>Ga-Pentixafor in solid tumours.https://www.mdpi.com/2075-4418/12/9/2135CXCR4PentixaforPET |
| spellingShingle | Bawinile Hadebe Machaba Michael Sathekge Colleen Aldous Mariza Vorster Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours Diagnostics CXCR4 Pentixafor PET |
| title | Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours |
| title_full | Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours |
| title_fullStr | Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours |
| title_full_unstemmed | Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours |
| title_short | Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours |
| title_sort | current status of sup 68 sup ga pentixafor in solid tumours |
| topic | CXCR4 Pentixafor PET |
| url | https://www.mdpi.com/2075-4418/12/9/2135 |
| work_keys_str_mv | AT bawinilehadebe currentstatusofsup68supgapentixaforinsolidtumours AT machabamichaelsathekge currentstatusofsup68supgapentixaforinsolidtumours AT colleenaldous currentstatusofsup68supgapentixaforinsolidtumours AT marizavorster currentstatusofsup68supgapentixaforinsolidtumours |